About Us

We are hiring!

If you are a recent graduate and interested in being a part of a highly motivated team on the ground level, check out our new posting!

Who we are

Metabolomic Technologies Inc. is a fast growing company specializing in the development of novel metabolomics-based diagnostics for the healthcare market.

Our lead product, PolypDx™ is an innovative urine-based screening test for the detection of colorectal cancer. 
Meet our team here

Where the innovation began

We are the legacy of our founder. The late Dr. Richard Fedorak was a visionary health sciences entrepreneur and world-leading gastroenterologist.  It was his vision that we can one day rid the world of colorectal cancer through an easier urine-based screening test. 

Along with his colleague, Dr. Haili Wang, he began the work to develop a test to detect colorectal cancer in its earliest stages.  Our team at MTI share this vision and will continue to take on the challenge of reducing the incidence of colorectal cancer through early detection.


Our flagship product

Our flagship product, PolypDx™, is a urine-based test with a high sensitivity for detecting adenomatous polyps, the precursor to colorectal cancer. PolypDx™ provides healthcare professionals with a tool for early screening and detection, enabling the timely removal of polyps before they progress to colorectal cancer, thereby preventing cancer in the first place.

View our accolades

Milestone Timeline


876-Patient Discovery Trial Completed


Validation Trials Completed


2M CAD Seed Round


PolypDx™ LDT Launched


Canadian Assessment of PolypDx™


2018 Economic Model showing PolypDx™ is cost-effective


US Patent Issued - Completing global IP coverage


Discovery & Validation on additional CRC markers


Closed 3.2M USD Series A Round